))
Cystic fibrosis (CF) is one of the most prevalent global congenital disorders, affecting some 70,000 individuals worldwide and 30,000 children and adults in the United States. While clinical efforts are expanding worldwide to improve diagnostic testing and treatment approaches for this progressive lung disease, targeted therapies for CF against any specific mutation remain elusive. The Cystic Fibrosis in Focus series gathers the latest information from leading medical experts devoted to adva ...
…
continue reading
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
…
continue reading
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
…
continue reading
Dig into the leading edge of pediatric research with scientists from Stanley Manley Children's Research Institute at the Ann & Robert H. Lurie Children's Hospital of Chicago, one of the nation's largest freestanding pediatric research centers. On each episode, Patrick Seed, MD, PhD, president and chief research officer of Stanley Manley Children's Research Institute, talks with experts chasing solutions to the most pressing health challenges faced by kids and teens today.
…
continue reading
In My Whey Podcast is hosted by me, Brian Geller, DC, a chiropractor out of Buffalo, NY. Originally started as a fanzine in the summer of 2011, In My Whey was created to capture all things strength in the hardcore/punk community. The fanzine embodied the DIY movement by self-publishing, editing and funding the entire project, with no ads nor sponsors. In My Whey Fanzine featured a wide range of interviews with people ranging from elite-level powerlifters, strength coaches, recreational lifte ...
…
continue reading
Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt instituti…
…
continue reading
CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/does-your-patient-have-pbc/29108/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies.…
…
continue reading
CME credits: 0.25 Valid until: 31-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/empowering-choices-navigating-early-stage-hr-her2-breast-cancer-with-cdk46-inhibition/26643/ Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiothera…
…
continue reading
Host: Joyce O'Shaughnessy, MD Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiotherapy or chemoradiotherapy, followed by adjuvant endocrine therapy for 5 to 10 years. Although endocrine therapy improves outcomes in these patients, recurrence is hi…
…
continue reading
1
Pulmonary Hypertension for Advanced Practice Providers: Risk Stratification and Diagnosis to Enhance Quality of Care and Outcomes
Host: Martha Kingman, DNP, FNP-C Guest: Susanne McDevitt, DNP, ACNP-BC This program focuses on early symptom identification and timely diagnosis in patients with pulmonary hypertension (PH). Learn how appropriate risk stratification can facilitate the effective management of PH. Our experts also stress the importance of asking the right questions a…
…
continue reading
1
Pulmonary Hypertension for Advanced Practice Providers: Risk Stratification and Diagnosis to Enhance Quality of Care and Outcomes
CME credits: 1.00 Valid until: 17-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-for-advanced-practice-providers-risk-stratification-and-diagnosis-to-enhance-quality-of-care-and-outcomes/27146/ This program focuses on early symptom identification and timely diagnosis in patients with pulmonary hypertension …
…
continue reading
Guest: C. Brendan Montano, MD Guest: Anton P. Porsteinsson, MD Early diagnosis and management of agitation in Alzheimer’s disease (AAD) is part of a comprehensive treatment plan. How can you help caregivers recognize subtle signs of AAD to facility early treatment? Our experts have the answers you need!…
…
continue reading
CME credits: 0.25 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-approaches-to-optimizing-outcomes-in-aad-case-review/26713/ Early diagnosis and management of agitation in Alzheimer’s disease (AAD) is part of a comprehensive treatment plan. How can you help caregivers recognize subtle signs of AAD …
…
continue reading
1
Advancing Cystic Fibrosis: Addressing Disparities, Challenging Perceptions, and Innovating Patient-Centered Care
CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancing-cystic-fibrosis-addressing-disparities-challenging-perceptions-and-innovating-patient-centered-care/24487/ Cystic Fibrosis (CF) care faces challenges from health disparities, limited access, and unintended bias, affecting patient outcomes. …
…
continue reading
CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/bridging-distances-in-pah-bringing-best-practices-to-the-people-through-telemonitoring/24051/ Pulmonary Arterial Hypertension (PAH) requires a personalized, multidisciplinary approach, which is often lacking in remote regions due to limited access to…
…
continue reading
Host: Jean M. Elwing, MD Host: Nicholas Kolaitis, MD, MAS Guest: Katharine Clapham, MD Pulmonary Arterial Hypertension (PAH) requires a personalized, multidisciplinary approach, which is often lacking in remote regions due to limited access to specialized care and resources. The scarcity of specialized PH centers forces reliance on general practiti…
…
continue reading
1
Advancing Cystic Fibrosis: Addressing Disparities, Challenging Perceptions, and Innovating Patient-Centered Care
Host: Denis Hadjiliadis, MD, MHS, PhD Guest: Gregory S. Sawicki, MD, MPH Guest: Alexandra Wilson, MS, RDN, CDE Guest: Susanna A. McColley, MD Cystic Fibrosis (CF) care faces challenges from health disparities, limited access, and unintended bias, affecting patient outcomes. This CME program aims to equip healthcare professionals with the skills nee…
…
continue reading
1
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
CME credits: 1.00 Valid until: 04-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/bringing-treatment-into-focus-biomarker-driven-first-line-therapy-for-metastatic-gastricgej-cancers/26719/ This educational activity delves into biomarker-driven strategies for first-line therapy in metastatic gastric and gastroesophageal junction (G…
…
continue reading
1
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
Host: David H. Ilson, MD, PhD Guest: Sunnie Kim, MD This educational activity delves into biomarker-driven strategies for first-line therapy in metastatic gastric and gastroesophageal junction (GEJ) cancers. Participants will explore the latest clinical trial data and emerging biomarkers that guide treatment decisions. Our experts emphasize selecti…
…
continue reading
CME credits: 0.25 Valid until: 04-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/navigating-copd-from-symptom-recognition-to-emerging-treatment-strategies/26928/ Listen in as Farrukh Abbas, MD, FCCP, and Megan Conroy, MD, MAEd, FCCP, discuss the role of the care team in COPD diagnosis, recent changes in classifications and update…
…
continue reading
Host: Farrukh Abbas, MD Guest: Megan Conroy, MD, MA(Ed) Listen in as Farrukh Abbas, MD, FCCP, and Megan Conroy, MD, MAEd, FCCP, discuss the role of the care team in COPD diagnosis, recent changes in classifications and updates to the GOLD guidelines, how triple-inhaler therapies and biologics can be used to treat patients with COPD, and more. Since…
…
continue reading
Guest: Gilberto de Lima Lopes, Jr, MD, MBA, FASCO Guest: Jyoti Patel, MD The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstr…
…
continue reading
CME credits: 0.75 Valid until: 02-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-role-of-met-tkis-in-nsclc/17986/ The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer…
…
continue reading
1
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
Host: Sara M. Tolaney, MD, MPH This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adv…
…
continue reading
1
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
CME credits: 0.25 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-redefining-treatment-across-the-spectrum-of-hrher2-expressing-metastatic-breast-cancer/26625/ This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast ca…
…
continue reading
1
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
CME credits: 0.25 Valid until: 25-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/implementing-a-multidisciplinary-approach-to-heart-failure-patient-identification-and-treatment-using-novel-device-therapy/16191/ Despite guideline-directed medical therapy, many patients with heart failure will continue to develop worsening symptoms…
…
continue reading
1
Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
Host: Amir T. Fathi, MD Guest: Courtney DiNardo, MD Guest: Brian A. Jonas, MD, PhD While the expanding arsenal of therapies available for patients with AML allows practitioners to further hone treatment and individualize care, the complexity of treatment decision-making requires careful consideration of potential risks and benefits of each treatmen…
…
continue reading
1
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Host: Christina Economides, MD Guest: Brian Howard, MD Guest: David N. Kenigsberg, MD, FACC Despite guideline-directed medical therapy, many patients with heart failure will continue to develop worsening symptoms and diminishing quality of life. Baroflex activation therapy (BAT) may be a treatment option for patients with heart failure with reduced…
…
continue reading
1
Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
CME credits: 1.00 Valid until: 25-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/mastering-the-complexity-of-aml-treatment-a-multidimensional-approach-to-diagnosis-therapy-and-side-effect-management/26723/ While the expanding arsenal of therapies available for patients with AML allows practitioners to further hone treatment and i…
…
continue reading
1
Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Host: Matthew S. Davids, MD, MMSc This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial practice gaps. Key challenges include managing poor treatment responses and patient health deterioration, nec…
…
continue reading
1
Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
CME credits: 1.00 Valid until: 24-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/noncovalent-btk-inhibitors-new-targeted-options-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma/24362/ This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, part…
…
continue reading
Host: Caroline Piatek, MD Guest: Irina Murakhovskaya, MD Warm autoimmune hemolytic anemia (wAIHA) is a rare condition characterized by the premature destruction of red blood cells mainly by pathogenic IgG optimally active at 37oC. Innovative targeted therapies to address wAIHA are emerging, and many are likely to greatly improve patient outcomes wh…
…
continue reading
CME credits: 0.25 Valid until: 18-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-antibody-based-therapies-are-revolutionizing-its-management/26371/ Warm autoimmune hemolytic anemia (wAIHA) is a rare condition characterized by the premature destruction of red blood cells mainly by pathogenic IgG optimally active at 37oC. Innov…
…
continue reading
Host: Helena Yu, MD The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emergin…
…
continue reading
CME credits: 0.50 Valid until: 13-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/targeting-resistance-in-egfrm-nsclc-with-her3-directed-adcs-in-the-community-setting/24489/ The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional…
…
continue reading
1
Expanding Cystic Fibrosis Treatment and Testing with Susanna McColley, MD
26:45
26:45
Nghe Sau
Nghe Sau
Danh sách
Thích
Đã thích
26:45
During more than three decades of her career in pediatric pulmonology, Susanna McColley, MD, has seen the average life expectancy for children with cystic fibrosis advance from teenage years to mid-50s. In this episode, Dr. McColley details the evolution of cystic fibrosis diagnosis and treatment and discusses how she is addressing the ongoing disp…
…
continue reading
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-evaluating-her2-directed-therapies-in-gynecologic-cancers/26792/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapie…
…
continue reading
Host: Shubham Pant, MD, MBBS This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumor…
…
continue reading
Host: Shubham Pant, MD, MBBS This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumor…
…
continue reading
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-how-do-her2-directed-therapies-fit-into-the-ovarian-cancer-treatment-landscape/26794/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications f…
…
continue reading
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/significance-of-her2-expression-in-solid-tumors/26788/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-…
…
continue reading
Host: Shubham Pant, MD, MBBS Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advance…
…
continue reading
Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors …
…
continue reading
1
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-how-do-her2-directed-therapies-fit-into-the-biliary-tract-cancer-treatment-landscape/26795/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implicat…
…
continue reading
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/her2-testing-strategies-across-tumor-types-amidst-guidelines-gaps/26789/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and …
…
continue reading
Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors …
…
continue reading
1
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors …
…
continue reading
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/monitoring-and-managing-treatment-related-adverse-effects-associated-with-her2-directed-agents/26793/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implication…
…
continue reading
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-on-targeting-her2-in-her2-expressing-solid-tumors/26791/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and cli…
…
continue reading
Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors …
…
continue reading
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/diversity-in-her2-expression-among-gynecologic-cancers/26790/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical de…
…
continue reading
Host: Shubham Pant, MD, MBBS Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advance…
…
continue reading
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-challenge-of-bcl-2-resistance-in-cll-treatment-strategies-and-emerging-therapies/26503/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients a…
…
continue reading
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-disease-progression-in-cll-evidence-based-re-treatment-considerations/26502/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are o…
…
continue reading
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/mrd-testing-to-guide-treatment-considerations-in-cll/26499/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present …
…
continue reading
